Neuroscience Applied最新文献

{"title":"Neuroinflammation in comorbid depression in Alzheimer's disease: A pilot study using post-mortem brain tissue","authors":"Jordan T. Lin ,&nbsp;Mizuki Morisaki ,&nbsp;Srisharnitha A. Sampathkumar ,&nbsp;Laurie C. Lau ,&nbsp;Delphine Boche ,&nbsp;Golam M. Khandaker ,&nbsp;Lindsey I. Sinclair","doi":"10.1016/j.nsa.2024.104051","DOIUrl":"10.1016/j.nsa.2024.104051","url":null,"abstract":"<div><p>Comorbid depression and Alzheimer's disease (AD) is associated with poorer prognosis than either condition alone. Neuroinflammation has been implicated in the pathogenesis and progression of both depression and AD, but much of the existing research has been based on peripheral blood immune markers. Relatively little is known about the neuroinflammatory environment when these conditions occur simultaneously and using immune measures directly in the brain tissue. This pilot study aimed to examine brain inflammatory marker changes in AD cases comparing those with and without comorbid depression.</p><p>Post-mortem brain tissue from AD cases with depression (n = 23) and AD cases with no history of psychiatric illness (n = 25) were analyzed for a range of inflammatory markers, including markers of microglial function (Iba1, P2RY12, CD64 and CD68 measured by immunohistochemistry); endothelial inflammatory markers (ICAM-1 and VCAM-1 measured by ELISA); and cytokine levels (IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-α measured using Mesoscale Discovery Multiplex Assays).</p><p>Brains of AD cases with comorbid depression, compared with AD alone, had increased IL-4 in the superior frontal gyrus and increased TNFα &amp; IL-12p70 in the insula. Levels of all other inflammatory markers including markers of microglial function and endothelial inflammation were similar between the two groups.</p><p>We found no consistent changes in cytokines between the two brain regions in individuals with comorbid depression in AD. Further work in larger cohorts is needed to understand brain region specificity of immune marker alterations and the relationship of these changes with pre-mortem clinical outcomes.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104051"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001169/pdfft?md5=181de25a9584c1ea819137ead5df6f44&pid=1-s2.0-S2772408524001169-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140084729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colour vision impairments in bipolar disorder: A systematic review","authors":"Jason Tran ,&nbsp;Arnav Gupta ,&nbsp;Nicholas Fabiano ,&nbsp;Vinita Dhir ,&nbsp;Katherine Larose ,&nbsp;Iris Lasker ,&nbsp;Stanley Wong ,&nbsp;Ibrahim Y.Z. Mohammad ,&nbsp;Steven Le ,&nbsp;Jess G. Fiedorowicz ,&nbsp;Risa Shorr ,&nbsp;Andrea Zampieri ,&nbsp;Alessio Bellato ,&nbsp;Samuele Cortese ,&nbsp;Marco Solmi","doi":"10.1016/j.nsa.2024.104057","DOIUrl":"10.1016/j.nsa.2024.104057","url":null,"abstract":"<div><p>Visual impairments are common in patients with bipolar disorder (BD), and the neuropathophysiology may suggest a potential influence on colour vision. This systematic review aimed to assess existing data of colour vision impairment, including chromatic discrimination and colour blindness in patients with BD. Comprehensive literature search compliant with PRISMA 2020 was conducted in Medline, Embase, and Google Scholar from inception to February 28th, 2023. Our inclusion criteria were: (1) patients with a diagnosis of bipolar I or II disorder based on DSM, ICD, or clinical diagnosis, and (2) study investigating colour vision (i.e., including colour blindness and discrimination), with (3) no restrictions on the condition of the comparator group. Study quality appraisal was performed using the NIH Study Quality Assessment Tool. Five studies from Brazil, Netherlands, and USA, with 338 patients were included. Three cross-sectional studies assessed chromatic discrimination and two case-series assessed colour blindness in patients with BD. The three cross-sectional studies support reduced chromatic discrimination during mild to moderate mania in BD when compared to healthy comparators. The latter two articles presented low evidence of an X-linked inheritance of BD. Our review indicates evidence of reduced chromatic discrimination in mild to moderate mania. However, further research is needed to validate these findings and to extend to other mood states in BD given current limitations. Future studies can benefit from further multi-institutional data, larger sample sizes, appropriate blinding, the use of biomarkers, and statistical adjustment to confounders to fully elucidate the role of chromatic discrimination in BD.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104057"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001224/pdfft?md5=8a56ac6cb53f7a84d23224c57df6b12e&pid=1-s2.0-S2772408524001224-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140283208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A machine learning pipeline for efficient differentiation between bipolar and major depressive disorder based on multimodal structural neuroimaging","authors":"Federico Calesella ,&nbsp;Federica Colombo ,&nbsp;Beatrice Bravi ,&nbsp;Lidia Fortaner-Uyà ,&nbsp;Camilla Monopoli ,&nbsp;Sara Poletti ,&nbsp;Emma Tassi ,&nbsp;Eleonora Maggioni ,&nbsp;Paolo Brambilla ,&nbsp;Cristina Colombo ,&nbsp;Irene Bollettini ,&nbsp;Francesco Benedetti ,&nbsp;Benedetta Vai","doi":"10.1016/j.nsa.2023.103931","DOIUrl":"10.1016/j.nsa.2023.103931","url":null,"abstract":"<div><p>Due to the overlapping depressive symptomatology with major depressive disorder (MDD), 60% of patients with bipolar disorder (BD) are initially misdiagnosed, calling for the definition of reliable biomarkers that can support the diagnostic process. Here, we optimized a machine learning pipeline for the differentiation between depressed BD and MDD patients based on multimodal structural neuroimaging features. Diffusion tensor imaging (DTI) and T1-weighted magnetic resonance imaging (MRI) data were acquired for 282 depressed BD (n = 180) and MDD (n = 102) patients. Images were preprocessed to obtain axial (AD), radial (RD), mean (MD) diffusivity, fractional anisotropy (FA), and voxel-based morphometry (VBM) maps. Each feature was entered separately into a 5-fold nested cross-validated predictive pipeline differentiating between BD and MDD patients, comprising: confound regression for nuisance variables removal, feature standardization, principal component analysis for feature reduction, and an elastic-net penalized regression. The DTI-based models reached accuracies ranging from 75% to 78%, whereas the VBM model reached 61% of accuracy. All the models were significantly different from a null model distribution at a 5000-permutation test. A 5000 bootstrap procedure revealed that widespread differences drove the classification, with BD patients associated to overall higher values of AD and FA, and grey matter volumes. Our results suggest that structural neuroimaging, in particular white matter microstructure and grey matter volumes, may be able to differentiate between MDD and BD patients with good predictive accuracy, being significantly higher than chance-level.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 103931"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408523029137/pdfft?md5=4ae53c21a2570d689b748b56bb864848&pid=1-s2.0-S2772408523029137-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139024196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nose to brain delivery of flurbiprofen from a solid lipid nanoparticles-based thermosensitive in-situ gel.","authors":"Ashok J. Choudhary,&nbsp;Sakshi S. Mahajan,&nbsp;Anuradha S. Majumdar","doi":"10.1016/j.nsa.2024.104062","DOIUrl":"https://doi.org/10.1016/j.nsa.2024.104062","url":null,"abstract":"<div><p>Flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID), has selective amyloid-lowering characteristics and can be utilized for Alzheimer's disease treatment. Oral flurbiprofen has poor brain bioavailability and high dose-related gastrointestinal adverse effects. To overcome these issues, the study aimed to formulate intranasal flurbiprofen solid lipid nanoparticles (SLN) based thermosensitive <em>in-situ</em> gel. SLN were formulated by the High-speed homogenization method. A 2³ factorial design technique was utilized for optimization, wherein the influence of two independent variables, critical process parameters (X₁ = surfactant concentration, X₂ = D:L ratio) on critical quality attributes (Y₁ = particle size, Y₂=Percent Drug Loading, Y₃=Percent Entrapment Efficiency) was ascertained at three distinct levels. The optimized SLN were then prepared into an SLN-based intranasal thermosensitive <em>in-situ</em> gel with Poloxamer 188 P (1.2% w/v) and Poloxamer 407 P (18% w/v). The <em>in-vitro</em> flurbiprofen release study demonstrated a 100% release of flurbiprofen from the SLN-based thermosensitive <em>in-situ</em> gel at 6 h. The <em>ex-vivo</em> flurbiprofen release study revealed a complete release of flurbiprofen from the SLN-based thermosensitive <em>in-situ</em> gel at 8 h. In the <em>in-vivo</em> tests, the <em>in-situ</em> gel (2 mg/kg) administered intranasally in rats demonstrated nearly three times greater brain bioavailability (C_max = 490.3 ng/ml) than the oral marketed formulation of flurbiprofen, Ansaid® (10 mg/kg) (C_max = 145.1 ng/ml). The plasma concentration obtained with intranasal <em>in-situ</em> gel (C_max = 2.5 μg/ml) was lower than the oral marketed formulation (C_max = 3.4 μg/ml). The time necessary to establish the maximal flurbiprofen concentration (T_max) in the brain was 2 and 0.5 h for oral and intranasal formulations, respectively. Hence, the intranasal formulation could achieve maximal drug concentration in the brain in less time. Thus, flurbiprofen SLN-based thermosensitive <em>in-situ</em> gel can be a potential encouraging safe, non-invasive, and efficacious replacement to oral formulations for achieving direct brain targeting through nose-to-brain drug delivery, thereby treating neuroinflammatory conditions like Alzheimer's disease.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104062"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001273/pdfft?md5=44c56390985a14af37a9af479da27b33&pid=1-s2.0-S2772408524001273-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurobiological traces of grief: Examining the impact of offspring loss after birth on rat mothers’ brain and stress-coping behavior in the first week postpartum","authors":"Luisa Demarchi,&nbsp;Alice Sanson,&nbsp;Oliver J. Bosch","doi":"10.1016/j.nsa.2024.104065","DOIUrl":"https://doi.org/10.1016/j.nsa.2024.104065","url":null,"abstract":"<div><p>The bond between a mother and her infant is one of the strongest social bonds found in mammals. Consequently, the loss of an infant has immense psychological and physiological effects on the caregiver. Despite the significance of this bereavement, only a few studies have investigated the neurobiological impact of offspring loss in mothers. In an approach to fill this gap, we studied the effects of losing all pups the day after giving birth on rat mothers' brain and stress-coping behavior. Specifically, dams experienced 1-, 3-, or 6-days of total offspring loss. We analyzed the neuronal activity and oxytocin receptor (OXT-R) binding in the brain limbic and maternal network regions, as well as the stress response and stress-coping strategies. Following 1 day of loss, the mothers' neuronal activity increased in the limbic system resulting in a positive correlation between the prelimbic cortex and basolateral amygdala, while OXT-R binding was decreased in the central amygdala following up to 3 days of loss. At all three timepoints, plasma corticosterone concentrations did not differ either under basal conditions or following stressor exposure. Remarkably, following 6 days of offspring loss, the mothers showed a significant increase in passive stress-coping behavior, marking the first evidence of offspring loss affecting rat mothers' stress-coping behavior. Our results emphasize the significant impact of offspring loss on the mothers’ neuronal activity and brain oxytocin system thereby providing novel insight into the short-term neurobiological traces of grief and paving new avenues for future research in this field.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104065"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001303/pdfft?md5=7f84ccdae9babd7491b858094f6f8932&pid=1-s2.0-S2772408524001303-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140555377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling","authors":"Karlijn L. Kooij ,&nbsp;Derek IJsbrand Koster ,&nbsp;Emma Eeltink ,&nbsp;Mieneke Luijendijk ,&nbsp;Lisa Drost ,&nbsp;Fabien Ducrocq ,&nbsp;Roger A.H. Adan","doi":"10.1016/j.nsa.2023.103925","DOIUrl":"10.1016/j.nsa.2023.103925","url":null,"abstract":"<div><p>Semaglutide, a glucagon-like peptide-1 receptor agonist, is an effective drug reducing body weight and decreasing motivation for palatable food. The mechanisms underlying its effects on food reward remain unclear. We aimed to determine the impact of semaglutide on food reward collection and dopamine-neuron activity in the ventral tegmental area (VTA) upon exposure to a cue-induced sucrose delivery task.</p><p>Pitx3-cre mice were injected with cre-dependent GCaMP6s virus into the VTA, to measure the activity of dopaminergic neurons in the VTA using <em>in vivo</em> fiber photometry. Mice were trained on a Pavlovian sucrose conditioning paradigm in which a 5-s cue signaled a 20% sucrose reward. Upon stable performance, semaglutide or vehicle was intraperitoneally injected during the task.</p><p>1 mg/kg semaglutide reduced the number of collected rewards and licks during the task. Semaglutide increased VTA dopamine neuron activity during sucrose collection but not during the cue. Lower doses of semaglutide (0.1 and 0.3 mg/kg) reduced chow intake but not sucrose intake nor VTA dopamine activity in the task.</p><p>Semaglutide reduces appetite but increases VTA dopamine signaling during reward collection. Semaglutide does not influence dopamine signaling during the presentation of food cues.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 103925"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408523029071/pdfft?md5=8d4cf17dae0cb257ea4e3ebcbf76d56a&pid=1-s2.0-S2772408523029071-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139291177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive inflexibility, obsessive-compulsive symptoms and traits and poor post-pandemic adjustment","authors":"Ana Maria Frota Lisboa Pereira de Souza ,&nbsp;Luca Pellegrini ,&nbsp;Naomi Anne Fineberg","doi":"10.1016/j.nsa.2024.104073","DOIUrl":"10.1016/j.nsa.2024.104073","url":null,"abstract":"<div><p>The ability to flexibly adapt thoughts and behaviours represents a fundamental attribute for behavioural success. Impairments in aspects of cognitive flexibility are found as transdiagnostic latent phenotypes of obsessive-compulsive symptomatology and are present within a range of mental disorders and within the population at large. In this narrative review, we focus on the attentional set-shifting aspect of cognitive inflexibility, which has been largely investigated in the context of obsessive-compulsive spectrum disorders and is thought to underpin perseverative symptomatology. We appraise the published literature relating to the putative neurobiological mechanisms, methods of assessment, interventional approaches, and health and wellbeing impacts. We discuss critical knowledge gaps, promising new research avenues, and potential interventional approaches from a clinical and public health perspective. We conclude that cognitive inflexibility has relevance for clinicians in terms of understanding clinical outcomes and tailoring personalised forms of treatments, and for public health professionals in terms of understanding rigid attitudes and adjustment in the current post-pandemic environment.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104073"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001388/pdfft?md5=1845283755c134388f1679a29230296e&pid=1-s2.0-S2772408524001388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in older-aged and younger-aged bipolar I patients treated with cariprazine for acute mania: a post-hoc analysis","authors":"N. Garel ,&nbsp;A. Dols ,&nbsp;J. Yu ,&nbsp;C. Di Cresce ,&nbsp;S. Rej ,&nbsp;M. Sajatovic","doi":"10.1016/j.nsa.2024.104184","DOIUrl":"10.1016/j.nsa.2024.104184","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104184"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143091971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal diet during pregnancy and lactation affects cytochrome P450 2D (CYP2D) in the liver and brain of male rat offspring","authors":"A. Haduch ,&nbsp;W. Kuban ,&nbsp;E. Bromek ,&nbsp;A. Basińska-Ziobroń ,&nbsp;K. Gawlińska ,&nbsp;M. Filip ,&nbsp;W.A. Daniel","doi":"10.1016/j.nsa.2024.104136","DOIUrl":"10.1016/j.nsa.2024.104136","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104136"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene expression of protein synthesis, brain and immunity pathways specifically modified in Anorexia nervosa","authors":"N. Ramoz ,&nbsp;C. Veribi ,&nbsp;N. Lebrun ,&nbsp;P. Duriez ,&nbsp;P. Gorwood ,&nbsp;T. Bienvenu","doi":"10.1016/j.nsa.2024.104138","DOIUrl":"10.1016/j.nsa.2024.104138","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104138"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}